Clinical Trials
11 trialsNCT05537766 2026-03-10
ZUMA-25
Gilead Sciences
Phase 2 Terminated
NCT05714345 2026-03-02
EXPAND
Allogene Therapeutics
Phase 2 Terminated
NCT04678336 2025-10-15
CD123 Redirected T Cells for AML in Pediatric Subjects
University of Pennsylvania
Phase 1 Terminated
NCT05883449 2025-08-20
LuminICE-203
Affimed GmbH
Phase 2 Terminated
NCT05972720 2025-05-15
FIRCE-1
CARGO Therapeutics
Phase 2 Terminated
NCT03624036 2023-11-18
ZUMA-8
Gilead Sciences
Phase 1 Terminated
NCT03168438 2022-01-11
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
GlaxoSmithKline
Phase 1 Terminated
NCT03126864 2019-11-04
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01173679 2017-04-14
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
Massachusetts General Hospital
Phase 2 Terminated
NCT01578343 2016-04-15
ZOLINZA
Samsung Medical Center
Phase 2 Terminated
NCT00615589 2016-04-04
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
University of Michigan Rogel Cancer Center
Phase 2 Terminated